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Background
CD30+ T-cell lymphoproliferations comprise a spectrum of clinically heterogeneous entities,
including systemic anaplastic large cell lymphomas (ALK- and ALK+) and primary cutaneous
CD30+ T-cell lymphoproliferative disorders. While all these entities are characterized by prolif-
eration of highly atypical, anaplastic CD30+ T cells, the expression of T-cell specific antigens in
the tumor cells is not consistently detectable.  
Design and Methods
We evaluated biopsies from 19 patients with primary cutaneous CD30+ lymphoproliferative
disorders, 38 with ALK- and 33 with ALK+ systemic anaplastic large cell lymphoma. The biop-
sies were examined for the expression of T-cell receptoraβ/CD3 complex (CD3γ, δ, ε, ζ), tran-
scription factors regulating T-cell receptor expression (ATF1, ATF2, TCF-1, TCF-1a/LEF-1,
Ets1), and molecules of T-cell receptor-associated signaling cascades (Lck, ZAP-70, LAT, bcl-10,
Carma1, NFATc1, c-Jun, c-Fos, Syk) using immunohistochemistry. 
Results
In comparison to the pattern in 20 peripheral T-cell lymphomas, not otherwise specified, we
detected a highly disturbed expression of the T-cell receptor/CD3 complex, TCF-1, TCF-
1a/LEF-1, Lck, ZAP-70, LAT, NFATc1, c-Jun, c-Fos and Syk in most of the systemic anaplastic
large cell lymphomas. In addition, primary cutaneous CD30+ lymphoproliferative disorders
showed such a similar expression pattern to that of systemic anaplastic large cell lymphomas,
that none of the markers we investigated can reliably distinguish between these CD30+ T-cell
lymphoproliferations.  
Conclusions
Severely altered expression of the T-cell receptor/CD3 complex, T-cell receptor-associated tran-
scription factors and signal transduction molecules is a common characteristic of systemic and
cutaneous CD30+ lymphoproliferations, although the clinical behavior of these entities is very
different. Since peripheral T-cell lymphomas, not otherwise specified retain the full expression
program required for functioning T-cell receptor signaling, the differential expression of a sub-
set of these markers might be of diagnostic utility in distinguishing peripheral T-cell lym-
phomas, not otherwise specified from the entire group of CD30+ lymphoproliferations.
Key words: systemic and cutaneous CD30+ lymphoproliferations, anaplastic large cell lym-
phoma, lymphomatoid papulosis, ALCL, LyP, TCR.
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Introduction
CD30+ T-cell lymphoproliferations comprise a spectrum
of clinically heterogeneous entities, including systemic
anaplastic large cell lymphomas (ALCL) as well as primary
cutaneous CD30+ T-cell lymphoproliferative disorders.
Morphologically, these entities are characterized by the
proliferation of highly atypical, anaplastic CD30+ T cells.
Despite the frequent detection of clonally rearranged T-
cell receptor (TCR) genes, the expression of T-cell-specific
antigens in the tumor cells is not consistently detectable.1
Systemic ALCL comprise approximately 15% of all
peripheral T-cell lymphomas (PTCL) in Europe2 and are
divided into anaplastic lymphoma kinase (ALK) positive
and negative subgroups (ALK+ and ALK- systemic ALCL),
whereas primary cutaneous CD30+ T-cell lymphoprolifer-
ative disorders represent a spectrum of skin lesions with
diverging and in part overlapping clinical and morpholog-
ical features. CD30+ T-cell lymphoproliferative disorders
include primary cutaneous ALCL, lymphomatoid papulo-
sis and so-called borderline lesions,3-5 but even with the
knowledge of the clinical presentation and a detailed mor-
phological and immunohistochemical picture it is some-
times difficult, if not impossible, to classify a particular
cutaneous lesion correctly.
While the transforming properties of ALK over-expres-
sion have been clearly demonstrated,6,7 the transformation
mechanisms in ALK- systemic ALCL and primary cuta-
neous CD30+ T-cell lymphoproliferative disorders are
poorly understood. CD30 itself, a cytokine receptor
belonging to the tumor necrosis factor receptor superfam-
ily, has been a research focus over the past years, but
whether CD30 signaling leads to cell cycle arrest, apopto-
sis or even proliferation in CD30+ lymphoproliferations is
still a matter of debate.8-11
We previously showed that a unifying molecular defect
in ALCL, regardless of ALK-expression status, was a TCR
and CD3ε expression deficiency, which - in most cases -
was associated with lost or markedly reduced expression
of ZAP-70.1 The present study had three aims. First, we
wanted to expand our investigation of TCR-associated
molecules in systemic ALCL to include the expression of
the entire TCR/CD3 complex (i.e. all different CD3 mole-
cules), transcription factors responsible for TCR expres-
sion (ATF-1, ATF-2, TCF-1, TCF-1a/LEF-1, and Ets-1) as
well as key molecules involved in the signaling of the
TCR/CD3 complex (LAT, ZAP70, Syk, Lck, bcl-10,
Carma1, and the transcription factors NFATc1, c-Jun, c-
Fos). Second, we included primary cutaneous CD30+ T-cell
lymphoproliferative disorders in our study, since virtually
nothing is known about the expression of these molecules
in these lymphoproliferations. Finally, we wanted to iden-
tify differentially expressed markers that might be of help
in the routine setting in the differential diagnosis between
systemic ALCL and primary cutaneous CD30+ T-cell lym-
phoproliferative disorders, but also between CD30+ T-cell
proliferations and peripheral T-cell lymphomas, not other-
wise specified (PTCL-NOS).
Design and Methods
Characteristics of the study set
We analyzed paraffin-embedded lymph node or skin biopsies
from 38 patients with ALK- systemic ALCL, 33 with ALK+ sys-
temic ALCL and 19 with primary cutaneous CD30+ T-cell lympho-
proliferative disorders selected from the files of the Institute of
Pathology, University of Wuerzburg. Twenty lymph node biopsies
with infiltration by PTCL-NOS served as controls. Approval for
the entire study was obtained from the Ethics Committee,
Medical Faculty, University of Wuerzburg, Germany.
All biopsies were stained with hematoxylin and eosin, Giemsa,
periodic acid Schiff and an appropriate panel of immunohisto-
chemical stains to establish a diagnosis according to the World
Health Organization classification.3 Based on histological and clin-
ical features the 19 primary cutaneous CD30+ T-cell lymphoprolif-
erative disorders could be classified as lymphomatoid papulosis
type A (n=7), lymphomatoid papulosis type C (n=2), cutaneous
ALCL (n=6), and lymphomatoid papulosis-like cutaneous ALCL
(n=4). All cases were reviewed independently by up to four expert
hematopathologists (HKM-H, TR, AR, EG) and cases for which
there was not a consensus were excluded from the study.
Immunohistochemical analyses
Using conventional immunohistochemical single stains, we
investigated the expression of CD30 and ALK, as well as the
expression of the TCRa/β (βF1) and CD3 subunits (γ, δ, ε, ζ) that
compose the TCR-complex. Due to the lack of frozen tumor tis-
sue, the expression of TCRγ/δ could not be evaluated. In addition,
we analyzed the expression of the TCR-associated signal trans-
duction molecules ZAP-70 (ζ-associated protein of 70 kDa), LAT
(linker for the activation of T cells), Syk (spleen tyrosine kinase),
Lck, bcl-10, Carma1/CARD11 (caspase recruitment domain
(CARD), and membrane-associated guanylate kinase (MAGUK)-
containing scaffold protein) and the transcription factors NFATc1
(nuclear factor of activated T cells), c-Jun, and c-Fos. A schematic
overview of the TCR/CD3 associated signaling cascades is pre-
sented in Figure 1 in which the molecules that were investigated
in the present study are highlighted. Finally, we also studied the
expression levels of the transcription factors ATF-1, ATF-2 (activat-
ing transcription factors 1 and 2), TCF-1 (T-cell factor-1), TCF-
1a/LEF-1 (lymphoid enhancer factor-1) and Ets-1, which are
involved in the regulation of the expression of the various TCR
chains. All immunohistochemical analyses were performed
according to standard protocols using the AdvanceTM HRP
Detection kit (K4068) from Dako. The sources of primary antibod-
ies and their dilutions are listed in Online Supplementary Table S1. 
All staining results were recorded semi-quantitatively as nega-
tive (0), weakly positive (independently of the amount of positive
tumor cells) or moderately positive in less than 40% of tumor cells
(1), moderately or strongly positive in at least 40% of tumor cells
(2), and strongly positive in more than 80% of tumor cells (3).
Staining intensities in reactive cells (T cells for most of the mark-
ers, but also B cells and histiocytes, e.g. for Syk) were used as inter-
nal controls.
Statistics
Based on approximately equal variances of expression values
between different entities, statistical analysis was done using the
Wilcoxon-Mann-Whitney two-sample rank-sum test. P values less
than 0.05 were considered statistically significant.
Results
Immunohistochemical analyses of the T-cell
receptor/CD3 complex
Since a functional TCR/CD3 complex is composed of a
heterodimeric TCR (either a/β or γ/δ) and three dimers of
E. Geissinger et al.
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the four CD3 subunits (γ, δ, ε, ζ), we performed immuno-
histochemical stains for all of these components, except
for the γ/δ-TCR, since the respective antibody cannot be
used on paraffin-embedded tissue. Based on the estab-
lished idea that the TCR/CD3 complex can only be assem-
bled and transported to the cell membrane when all com-
ponents consist of correctly folded proteins, we expected
a membranous staining pattern for all or none of the pro-
teins. Interestingly, we detected weak to moderate cyto-
plasmic staining or a pattern, sometimes with a strong
staining, restricted to the Golgi complex/endoplasmic
reticulum for various combinations of the five molecules,
which is likely due to a prolonged degradation process.
Surprisingly, we detected clear, but unexplained membra-
nous staining for only one of the five molecules in 4/71 of
the systemic and 3/19 of the cutaneous CD30+ T-cell lym-
phoproliferative disorders. Moreover, in six of these seven
cases, CD3ε was the sole molecule showing a pattern of
membranous staining. 
Complete negativity for all five molecules was detected
in 7/38 ALK- systemic ALCL, 9/33 ALK+ systemic ALCL,
2/10 cutaneous ALCL, and 0/9 lymphomatoid papulosis.
Cytoplasmic positivity for only one component was
found in 9/38 ALK- systemic ALCL, 14/33 ALK+ systemic
ALCL, 0/10 cutaneous ALCL, and 2/9 lymphomatoid
papulosis, and was most often CD3ζ (12/26 cases) since
this is the only component that forms a homodimer and
is, therefore, likely protected from rapid degradation.
Cytoplasmic positivity for two, three or four components
in random combinations was seen in 16/38 ALK- systemic
ALCL, 9/33 ALK+ systemic ALCL, 3/10 cutaneous ALCL,
and 4/9 lymphomatoid papulosis. Only 2/38 ALK- sys-
temic ALCL, 0/33 ALK+ systemic ALCL, 3/10 cutaneous
ALCL, and 2/9 lymphomatoid papulosis showed cytoplas-
mic positivity for all five molecules. These results are
graphically summarized in Figure 2 and representative
immunohistochemical staining results are depicted in
Figure 3. A detailed statistical analysis of these expression
results revealed no significant differences among the vari-
ous CD30+ lymphoproliferations.
Among the 20 PTCL-NOS cases, we found two cases
without TCRβ expression but strong positivity for all CD3
molecules; thus, in these cases, the tumor cells most likely
belong to a TCRγ/δ population. In general, none of the
PTCL-NOS had loss of any CD3 molecule; however, in
5/20 PTCL-NOS the TCRβ expression could not be exam-
ined due to technical reasons.
Immunohistochemical analyses of transcription factors
regulating T-cell receptor expression
We next investigated five transcription factors known to
be involved in the regulation of the expression of the four
different TCR chains. As detailed in Online Supplementary
Table S2, we detected significantly reduced expression of
TCF-1 and TCF-1a/LEF-1 in the systemic and cutaneous
CD30+ lymphoproliferations as compared to in the PTCL-
NOS cases, while there were no significant differences in
the expression of ATF-1, ATF-2, and Ets-1. Moreover,
there was significantly lower expression for TCF-1 and
TCF-1a/LEF-1 in ALK+ systemic ALCL [complete TCF-1
negativity in 27/33 (82%) cases, complete TCF-1a/LEF-1
negativity in 32/33 (97%) cases] than in ALK- systemic
ALCL [complete TCF-1 negativity in 12/38 (32%) cases,
complete TCF-1a/LEF-1 negativity in 15/38 (40%) cases].
Interestingly, the level of expression of Ets-1 was signifi-
cantly higher in primary cutaneous CD30+ T-cell lympho-
proliferative disorders than in systemic ALCL, irrespective
of the ALK status. Characteristic stains for the transcrip-
tion factors can be viewed in Figure 3.
Immunohistochemical analyses of key molecules
involved in the T-cell receptor/CD3 complex signaling
cascades
Analyzing key molecules involved in the signal trans-
duction of the TCR/CD3 complex, we found the LAT,
ZAP-70, and NFATc1 were expressed at significantly lower
TCR deficiency in CD30+ lymphoproliferations
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Figure 1. Schematic overview of the TCR/CD3-associated signaling
cascades. Molecules investigated immunohistochemically are high-
lighted in dark gray boxes.
Figure 2. Bar chart of the TCR/CD3 complex expression data. For
each entity, the percentage of cases that express a certain number
of subunits (TCRβ, CD3δ, ε, γ, ζ) is plotted. Only cases for which
expression data for all five TCR/CD3 subunits could be obtained are
included [9 cases of lymphomatoid papulosis (LYP), 10 of cutaneous
ALCL (cALCL), 36 ALK- systemic ALCL (sALCL), 33 ALK+ systemic
ALCL (sALCL), 15 PTCL-NOS]. 
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levels in systemic and cutaneous CD30+ T-cell prolifera-
tions than in PTCL-NOS, whereas bcl10 and Carma1
expression were not significantly different. Interestingly,
the level of expression of bcl-10 was slightly, but signifi-
cantly, lower in ALK+ systemic ALCL than in the ALK-
form. Moreover, when systemic ALCL (irrespective of
their ALK status) were compared with primary cutaneous
CD30+ T-cell lymphoproliferative disorders, the former
showed a slight but significantly decreased expression of
ZAP-70, NFATc1, bcl-10, and Carma1.
Syk, a protein kinase highly related to ZAP-70 but phys-
iologically not expressed in mature T cells, was expressed
E. Geissinger et al.
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Figure 3. Immunostaining of TCR/CD3
complex subunits and transcription factors
regulating TCR expression. The left column
shows characteristic staining results for
lymphomatoid papulosis, the middle col-
umn shows results for an ALK- systemic
ALCL and the right column shows results
for an ALK+ systemic ALCL. Scoring results
are provided below the respective mole-
cule (from left to right). 
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to various degrees in 11/38 ALK- systemic ALCL, 21/33
ALK+ systemic ALCL, 3/10 cutaneous ALCL, and 3/9 lym-
phomatoid papulosis, while all 20 PTCL-NOS remained
negative, thus revealing a significant difference not only
between the CD30+ T-cell lymphoproliferations and
PTCL-NOS cases, but also between ALK- and ALK+ sys-
temic ALCL. There was no mutually exclusive staining
pattern for ZAP-70 and Syk within the CD30+ T-cell lym-
phoproliferations.
The most striking difference between the CD30+ lym-
phoproliferations and PTCL-NOS was found for Lck: this
marker was not found in 35/38 ALK- systemic ALCL,
TCR deficiency in CD30+ lymphoproliferations
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Figure 4. Immunostaining of TCR/CD3
complex-associated signal transduction
molecules. The left column shows char-
acteristic staining results for lymphoma-
toid papulosis, the middle column shows
results for an ALK- systemic ALCL, and
the right column shows results for an
ALK+ systemic ALCL. Scoring results are
provided below the respective molecule
(from left to right). 
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33/33 ALK+ systemic ALCL, 7/10 cutaneous ALCL, and
4/8 lymphomatoid papulosis, but was clearly expressed in
all 20 PTCL-NOS. Moreover, we detected a slight but sig-
nificant difference in Lck expression between the cases of
cutaneous and systemic CD30+ T-cell lymphoprolifera-
tions, with the former having a higher percentage of Lck-
positive cases. As for the transcription factors c-Jun and c-
Fos, there was an increased expression in the whole group
of CD30+ T-cell lymphoproliferations compared to PTCL-
NOS. Online Supplementary Table S2 summarizes these
results and characteristic immunohistochemical stains are
depicted in Figure 4. The complete raw data including the
results of all stains in all cases are provided in Online
Supplementary Table S3.
Discussion
The results of our study add more details on the distur-
bance of the TCR/CD3 complex and associated signaling
molecules in systemic ALCL and expand these observa-
tions to the group of primary cutaneous CD30+ T-cell lym-
phoproliferative disorders. 
A functional TCR/CD3 complex is crucial for T-cell
development, as well as for the activation and differentia-
tion of mature T cells. It is well known, that the TCRaβ
heterodimer is non-covalently associated with three
dimers formed by the four different CD3 chains (δε, γε,
ζζ). There is obligatory co-expression of the TCR with the
CD3 molecules, and the absence of any single subunit
results in a loss of surface expression of the whole com-
plex, and the expressed chains are retained in the endo-
plasmic reticulum or Golgi complex and degraded.12-14
We were surprised that our immunohistochemical
stains for all four different CD3-chains and the TCRβ-
chain revealed entirely random losses of various combina-
tions of the five molecules in most systemic and cutaneous
CD30+ T-cell lymphoproliferations. Usually, there is rapid
degradation of unassembled subunits, unless formation of
more stable heterodimers or even hexamers occurs, ren-
dering these subunits detectable by immunohistochemical
approaches. Since CDζ forms a homodimer, its half-life is
longer than that of the other CD3 chains when expressed
alone, well in line with our observation that positivity for
only one component was most often detected for CD3ζ.
Only very few cases showed cytoplasmic but not surface
positivity for all five molecules: these cases included two
ALK- systemic ALCL, three cutaneous ALCL and two
lymphomatoid papulosis. Since an immunohistochemical
analysis of the TCRa chain is technically not feasible, we
cannot rule out that the lack of the subunit in these few
cases was responsible for the failure of surface expression. 
Given that our data suggest an expression defect of at
least one subunit of the TCR/CD3 complex in virtually all
systemic and cutaneous CD30+ T-cell lymphoprolifera-
tions, we wondered whether this defect may be due to a
dysfunction of transcription factors regulating TCR/CD3
gene expression.15 Among the molecules for which
immunohistochemical staining results were reliable (ATF-
1, ATF-2, Ets-1, TCF-1, TCF-1a/LEF-1), only TCF-1 and
TCF-1a/LEF-1, two structurally related members of the
TCF family of HMG-box DNA-binding factors with large-
ly overlapping expression patterns,16,17 showed significant
differences in expression among the CD30+ lymphoprolif-
erations themselves, as well as compared to PTCL-NOS.
Specifically, both proteins were significantly down-regu-
lated in the whole group of CD30+ lymphoproliferations
in comparison to PTCL-NOS cases; moreover, both tran-
scription factors were almost absent from ALK+ ALCL,
although detectable in a subset of ALK- ALCL. This finding
is in slight contrast with that of Dorfman et al., who found
complete TCF-1 and TCF-1a/LEF-1 negativity in 30/30
cases of ALCL irrespective of their ALK status.18
It is well known that ATF-1 and ATF-2 regulate TCRa
and TCRβ gene transcription and that TCF-1 and TCF-
1a/LEF-1 regulate TCRa, β and TCRδ gene transcription,
while Ets-1 targets all four TCR chains, namely the TCRa,
TCRβ, TCRγ and TCRδ genes. In addition, CD3ε, CD4
and interleukin-2 genes are presumed target genes of TCF-
1, CD4 and Lck of Ets-1 and CD4 and CD3ε of TCF-
1a/LEF-1.15,19 Since we could not detect a clear-cut correla-
tion between expression of these transcription factors and
that of their target genes, it is unlikely that a transcription-
al malfunction is the primary cause of disturbed expres-
sion of the TCR/CD3 complex.
We next investigated whether the expression of key
molecules of the TCR/CD3 complex associated intracellu-
lar signaling cascades20-22 is also altered. As a major finding
in our study, confirming a briefly mentioned result from a
previous study on a small number of T-cell lymphomas,23
Lck protein expression was almost completely abrogated
in systemic ALCL and in more than half the cases of pri-
mary cutaneous CD30+ T-cell lymphoproliferative disor-
ders, whereas all cases of PTCL-NOS expressed Lck. In
normal T cells, Lck, a src kinase, is the first intracellular
signaling molecule that is activated following TCR liga-
tion.22,24 Why Lck is not expressed in systemic ALCL tumor
cells that lack expression of the TCR/CD3 complex any-
way is unclear. Perhaps, loss of Lck expression is just a
bystander phenomenon or represents ‘collateral damage’
in a tumor cell in which TCR/CD3 complex-associated
signaling is malfunctioning. Alternatively, loss of Lck
expression might provide an additional growth advantage
to the tumor cells independently of TCR signaling, e.g. by
abrogating the pro-apoptotic properties of Lck under spe-
cific circumstances.25
In a previous study, we had already demonstrated a loss
of ZAP-7022,26 expression in the majority of systemic
ALCL.1 Interestingly, the primary cutaneous CD30+ T-cell
lymphoproliferative disorders in this study showed a dif-
ferent picture. Only 16% of primary cutaneous CD30+ T-
cell lymphoproliferative disorders, but more than half of
the systemic ALCL displayed no or only very weak ZAP-
70 expression. Interestingly, Syk, a protein kinase molecu-
larly and functionally highly related to ZAP-70 and nor-
mally expressed in B cells,26-31 was aberrantly expressed in
29% of ALK- systemic ALCL, 64% ALK+ systemic ALCL,
and 32% of primary cutaneous CD30+ T-cell lymphopro-
liferative disorders, while all 20 PTCL-NOS remained neg-
ative. Thus, for unknown reasons, we were unable to
reproduce the results of Feldmann et al.32 who detected
Syk-positivity in nearly 100% of CD30+ T-cell lymphopro-
liferations and the vast majority of PTCL-NOS. Whether
Syk might constitute a promising new drug target in PTCL
will have to await larger, future studies. Given that Syk
and ZAP-70 may partially substitute each other in normal
and neoplastic B and T cells26,30,31 we investigated whether
Syk and ZAP-70 expression was mutually exclusive in
CD30+ T-cell lymphoproliferations. However, this turned
out not to be the case.
E. Geissinger et al.
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While most of the molecules discussed so far were
expressed in PTCL-NOS cases and significantly down-reg-
ulated in CD30+ T-cell lymphoproliferations, c-Jun and c-
Fos, forming the AP1 transcription complex,33 had
increased expression particularly in the group of ALK+
ALCL. Since the activation of both proteins cannot be the
consequence of TCR/CD3 complex signaling, other
potentially oncogenic mechanisms may account for the
increased expression of c-Jun and c-Fos in these cases. Our
results parallel data from another group comparing c-Jun
expression in CD30+ and CD30- lymphoproliferations.34
They reported c-Jun expression in more than 70% of sys-
temic ALCL and in around 50% of primary cutaneous
CD30+ T-cell lymphoproliferative disorders, while all
CD30- lymphomas (including 40 cases of PTCL-NOS)
remained negative. There are currently no data available
in the literature about c-Fos expression in systemic ALCL,
although Mao et al. have investigated the expression of c-
Fos and c-Jun in various cutaneous lymphomas. They
described that the two transcription factors are expressed
in only a small percentage of cutaneous ALCL and lym-
phomatoid papulosis.35
NF-κB transcription factors are thought to play impor-
tant roles in T-cell activation and development and vari-
able expression of NF-κB target genes has been reported in
PTCL. While published data on the potential role of NF-κB
in the various subgroups of PTCL remain – for the most
part – inconclusive, there is some evidence that NF-κB
expression may be lower in ALCL than in PTCL-NOS.36,37
Since in our hands none of the commercially available
antibodies directed against the NF-κB subunits led to reli-
able staining results, we decided to investigate the expres-
sion of the upstream located molecules Carma1/Card11
and Bcl-10 which are part of the trimolecular CBM-com-
plex that is assembled after TCR stimulation.38 Given that
there appeared to be no significant differences in expres-
sion in Bcl-10 and Carma1 when comparing the whole
group of systemic and primary cutaneous CD30+ lympho-
proliferations with PTCL-NOS, these proteins are unlikely
to be responsible for the varying activity of NF-κB and
expression of its target genes between PTCL subgroups. 
One goal of our study was to compare the expression of
the TCR/CD3 complex and its associated signaling mole-
cules and transcription factors between systemic ALCL and
primary cutaneous CD30+ T-cell lymphoproliferative disor-
ders. In general, the expression of these proteins in primary
cutaneous CD30+ T-cell lymphoproliferative disorders par-
alleled that in systemic ALCL. However, it seems that there
may be a ‘gradient’, with the lowest disturbance in primary
cutaneous CD30+ T-cell lymphoproliferative disorders, an
intermediate disturbance in ALK- systemic ALCL and the
highest degree of disturbance in ALK+ systemic ALCL. The
minor differences we found between expression in pri-
mary cutaneous CD30+ T-cell lymphoproliferative disor-
ders and systemic ALCL are surprising, given the dramatic
discrepancy in the clinical presentation and prognosis
between these entities. However, a recent gene expression
profiling study also revealed highly related expression sig-
natures between primary cutaneous ALCL and systemic
ALCL,36 in concordance with our results. Nevertheless, sta-
tistical analysis demonstrated some significant differences
between primary cutaneous CD30+ T-cell lymphoprolifer-
ative disorders and systematic ALCL for the expression of
ATF-1, Ets-1, ZAP-70, NFATc1, c-Fos, bcl10, Carma1, and
Lck, while no obvious divergent expression profile was evi-
dent between cases of lymphomatoid papulosis and cuta-
neous ALCL. However, the utility of these markers is of
limited value in routine diagnosis of cutaneous infiltrates,
since no single marker or a panel of markers can reliably
differentiate between a primary or secondary cutaneous
CD30+ lymphoproliferation. 
In contrast, several markers may be of diagnostic value
in distinguishing between ALK- systemic ALCL and PTCL-
NOS. This differential diagnosis is sometimes difficult,
especially in highly pleomorphic CD30+ lymphomas. Our
series contained two consistently CD30+ and four partially
CD30+ PTCL-NOS cases that did not differ in their
immunohistochemical expression profile from the remain-
ing PTCL-NOS. We would argue that a loss of any of the
CD3 subunits in the tumor cells would strongly favor the
diagnosis of systemic ALCL or a primary cutaneous
CD30+ T-cell lymphoproliferative disorder. Moreover, a
panel of antibodies including NFATc1, TCF-1, TCF-
1a/LEF-1, LAT, Syk, Lck, c-Jun, and c-Fos might be of help
in cases in which staining for the CD3 subunits is incon-
clusive, although no single marker is able to make a robust
distinction. 
In conclusion, our results shed further light on the dis-
turbance of the TCR/CD3 complex, associated signaling
cascades and transcription factors in systemic ALCL,
which appears to parallel the situation in classical
Hodgkin’s lymphoma in which there is usually a lack of
expression of B-cell receptor and other characteristic B-cell
markers.39,40 Furthermore, primary cutaneous CD30+ T-cell
lymphoproliferative disorders are highly similar to sys-
temic ALCL with regards to their expression profile of
TCR-associated molecules, even though their clinical
behaviors differ significantly. In contrast, PTCL-NOS
retain the full expression program of proteins required for
a functioning TCR signaling. This biological feature might
be of diagnostic utility in distinguishing PTCL-NOS from
the entire group of CD30+ T-cell lymphoproliferations.
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